MA52655A - Biomarqueurs pour maladie cutanée inflammatoire - Google Patents
Biomarqueurs pour maladie cutanée inflammatoireInfo
- Publication number
- MA52655A MA52655A MA052655A MA52655A MA52655A MA 52655 A MA52655 A MA 52655A MA 052655 A MA052655 A MA 052655A MA 52655 A MA52655 A MA 52655A MA 52655 A MA52655 A MA 52655A
- Authority
- MA
- Morocco
- Prior art keywords
- biomarkers
- skin disease
- inflammatory skin
- inflammatory
- disease
- Prior art date
Links
- 201000004624 Dermatitis Diseases 0.000 title 1
- 239000000090 biomarker Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Data Mining & Analysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Software Systems (AREA)
- Signal Processing (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Primary Health Care (AREA)
- Evolutionary Biology (AREA)
- Evolutionary Computation (AREA)
- Theoretical Computer Science (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650636P | 2018-03-30 | 2018-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52655A true MA52655A (fr) | 2021-02-17 |
Family
ID=66448609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052655A MA52655A (fr) | 2018-03-30 | 2019-03-29 | Biomarqueurs pour maladie cutanée inflammatoire |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11584961B2 (fr) |
| EP (1) | EP3775284A1 (fr) |
| JP (1) | JP7565798B2 (fr) |
| MA (1) | MA52655A (fr) |
| WO (1) | WO2019191679A1 (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2888816A1 (fr) * | 2012-11-01 | 2014-05-08 | Incyte Corporation | Derives de thiophene condenses tricycliques a titre d'inhibiteurs de jak |
| BR122023022189A2 (pt) | 2018-02-16 | 2024-02-20 | Incyte Corporation | Usos de inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas |
| CN112423759A (zh) | 2018-03-30 | 2021-02-26 | 因赛特公司 | 使用jak抑制剂治疗化脓性汗腺炎 |
| MX2020010815A (es) | 2018-04-13 | 2020-12-11 | Incyte Corp | Biomarcadores para enfermedad de injerto contra hospedero. |
| EA202191170A1 (ru) | 2018-10-31 | 2021-07-27 | Инсайт Корпорейшн | Комбинированная терапия для лечения гематологических заболеваний |
| WO2020252012A1 (fr) | 2019-06-10 | 2020-12-17 | Incyte Corporation | Traitement topique du vitiligo par un inhibiteur de jak |
| ES3019413T3 (en) * | 2019-09-11 | 2025-05-20 | Pfizer | Treatment of hidradenitis suppurativa with a jak inhibitor |
| US12360120B2 (en) | 2019-10-10 | 2025-07-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| JP2022551649A (ja) | 2019-10-10 | 2022-12-12 | インサイト・コーポレイション | 移植片対宿主病のバイオマーカー |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| WO2021076124A1 (fr) * | 2019-10-16 | 2021-04-22 | Incyte Corporation | Utilisation d'inhibiteurs de jak1 pour le traitement du lupus érythémateux cutané et du lichen plan (l.p.) |
| CN113440613A (zh) * | 2020-03-26 | 2021-09-28 | 轶诺(浙江)药业有限公司 | 小檗碱类似物与jak抑制剂在胃肠道炎症性疾病治疗中的用途 |
| US20230203493A1 (en) * | 2020-05-31 | 2023-06-29 | Qingdao Medintell Biomedical Co., Ltd | Biomarkers Related to Oral Squamous Cell Carcinoma and Methods of Diagnosis and Treatment Thereof |
| CN113876956B (zh) * | 2020-07-01 | 2023-07-04 | 陈敏 | Pcsk9抑制剂在制备促进皮肤色素生成产品中的应用 |
| KR102519971B1 (ko) * | 2020-07-31 | 2023-04-11 | 서울대학교병원 | 염증성 질환의 예방 또는 치료용 조성물 및 이의 용도 |
| CN114107474B (zh) * | 2020-08-28 | 2024-05-07 | 复旦大学附属华山医院 | Anxa6多态性位点作为基因标志物以及和甲氨蝶呤联合的银屑病试剂盒 |
| JP2023544728A (ja) * | 2020-10-02 | 2023-10-25 | インサイト・コーポレイション | 扁平苔癬の治療のための局所ルキソリチニブ |
| CN112458173B (zh) * | 2020-11-27 | 2025-10-17 | 湖南中南大学湘雅口腔医院 | 一种诊断和治疗口腔鳞癌的生物标志物及其应用 |
| KR20230165746A (ko) | 2020-11-30 | 2023-12-05 | 민데라 코포레이션 | 마이크로니들 디바이스 및 방법, 및 피부 병태 어세이 |
| PL4255442T3 (pl) * | 2020-12-04 | 2025-09-01 | Incyte Corporation | Inhibitor jak z analogiem witaminy d do leczenia chorób skóry |
| WO2022125670A1 (fr) | 2020-12-08 | 2022-06-16 | Incyte Corporation | Inhibiteurs de la voie jak1 destinés au traitement du vitiligo |
| CN112795656B (zh) * | 2021-02-24 | 2022-11-04 | 湖南中南大学湘雅口腔医院 | 与口腔鳞癌发生发展相关的生物标志物及其在诊疗中的应用 |
| WO2022186296A1 (fr) * | 2021-03-02 | 2022-09-09 | 花王株式会社 | Procédé de détection de la détérioration de la gravité de la dermatite atopique |
| CN116144621A (zh) * | 2021-04-28 | 2023-05-23 | 杨森 | 一种皮肤年轻化蛋白标志物-acly蛋白及其无创提性取方法 |
| DK4333840T3 (da) | 2021-05-03 | 2025-11-24 | Incyte Corp | Jak1-vejinhibitorer til behandling af prurigo nodularis |
| CN113337504A (zh) * | 2021-05-27 | 2021-09-03 | 杭州医学院 | 一种长非编码rna及其在诊断及治疗原发性肝癌中的应用 |
| KR102778944B1 (ko) * | 2021-09-08 | 2025-03-11 | 렉스소프트 주식회사 | 아토피 피부염의 발병 위험도 진단을 위한 정보제공 방법 |
| CN114164211B (zh) * | 2021-09-16 | 2024-02-27 | 中国人民解放军海军军医大学 | lncRNA及其在肿瘤诊断、治疗和预后判断中的应用 |
| CN113789328A (zh) * | 2021-09-16 | 2021-12-14 | 中国人民解放军海军军医大学 | lncRNA及其在免疫调控及免疫相关疾病诊治中的应用 |
| CN116254343B (zh) * | 2023-02-22 | 2024-04-16 | 深圳市第二人民医院(深圳市转化医学研究院) | Rp11-713m15.2在制备治疗癌症的药物中的用途 |
| WO2024196761A1 (fr) * | 2023-03-17 | 2024-09-26 | Mayo Foundation For Medical Education And Research | Utilisation d'inhibiteurs oraux de janus kinase pour traiter le lichen plan |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| CA2439402A1 (fr) | 2001-03-02 | 2002-09-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Procede de reaction en chaine de la polymerase |
| US6812341B1 (en) | 2001-05-11 | 2004-11-02 | Ambion, Inc. | High efficiency mRNA isolation methods and compositions |
| EP1441737B1 (fr) | 2001-10-30 | 2006-08-09 | Novartis AG | Derives de staurosporine inhibiteurs de l'activite tyrosine kinase du recepteur flt3 |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| US7252976B2 (en) | 2002-08-28 | 2007-08-07 | Board Of Regents The University Of Texas System | Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| WO2005105814A1 (fr) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Inhibiteurs tetracycliques de janus kinases |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| US20070149506A1 (en) | 2005-09-22 | 2007-06-28 | Arvanitis Argyrios G | Azepine inhibitors of Janus kinases |
| KR101391900B1 (ko) | 2005-12-13 | 2014-05-02 | 인사이트 코포레이션 | 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘 |
| EP2121692B1 (fr) | 2006-12-22 | 2013-04-10 | Incyte Corporation | Hétérocycles substitués servant d'inhibiteurs de janus kinases |
| WO2008157208A2 (fr) | 2007-06-13 | 2008-12-24 | Incyte Corporation | Sels de l'inhibiteur (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile de la janus kinase |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| CN101910152B (zh) | 2007-11-16 | 2014-08-06 | 因塞特公司 | 作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺 |
| MX2010010012A (es) | 2008-03-11 | 2010-10-20 | Incyte Corp | Derivados de azetidina y ciclobutano como inhibidores de jak. |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| JOP20190230A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| DK2432472T3 (da) | 2009-05-22 | 2019-11-18 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer |
| TW201100429A (en) | 2009-05-22 | 2011-01-01 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| ES2435491T3 (es) | 2009-10-09 | 2013-12-19 | Incyte Corporation | Derivados de hidroxilo, ceto y glucurónido de 3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo |
| JP5858434B2 (ja) | 2010-02-18 | 2016-02-10 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体 |
| PH12015502575A1 (en) | 2010-03-10 | 2017-04-24 | Incyte Corp | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| EP3087972A1 (fr) | 2010-05-21 | 2016-11-02 | Incyte Holdings Corporation | Formulation topique pour un inhibiteur jak |
| CA2818545C (fr) | 2010-11-19 | 2019-04-16 | Incyte Corporation | Pyrrolopyridines et pyrrolopyrimidines a substitution heterocyclique utilisees en tant qu'inhibiteurs des jak |
| CN103415515B (zh) | 2010-11-19 | 2015-08-26 | 因塞特公司 | 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物 |
| PL2675451T3 (pl) | 2011-02-18 | 2016-05-31 | Novartis Pharma Ag | Terapia skojarzona z inhibitorem mTOR/JAK |
| US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| WO2013023119A1 (fr) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | Polythérapie par jak p13k/mtor |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| SMT202500302T1 (it) | 2012-06-15 | 2025-09-12 | Sun Pharmaceutical Industries Inc | Derivati deuterati del ruxolitinib |
| ES2717279T3 (es) | 2012-08-17 | 2019-06-20 | Concert Pharmaceuticals Inc | Baricitinib deuterada |
| CA2888816A1 (fr) | 2012-11-01 | 2014-05-08 | Incyte Corporation | Derives de thiophene condenses tricycliques a titre d'inhibiteurs de jak |
| EP3949953A1 (fr) | 2012-11-15 | 2022-02-09 | Incyte Holdings Corporation | Formes posologiques à libération prolongée de ruxolitinibe |
| BR112015021458B1 (pt) | 2013-03-06 | 2022-06-07 | Incyte Holdings Corporation | "processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases |
| UA117830C2 (uk) | 2013-05-17 | 2018-10-10 | Інсайт Корпорейшн | Похідні біпіразолу як інгібітори jak |
| WO2015021153A1 (fr) | 2013-08-07 | 2015-02-12 | Incyte Corporation | Formes galéniques à libération prolongée pour un inhibiteur jak1 |
| TW201529074A (zh) | 2013-08-20 | 2015-08-01 | Incyte Corp | 在ｃ-反應蛋白含量較高之實體腫瘤患者中的存活益處 |
| SI3110409T1 (sl) | 2014-02-28 | 2018-11-30 | Incyte Corporation | Inhibitorji JAK1 za zdravljenje mielodisplastičnih sindromov |
| CR20160553A (es) | 2014-04-30 | 2017-04-25 | Incyte Corp | Procesos para preparar un inhibidor de jak1 y nuevas formas de este |
| WO2015184305A1 (fr) | 2014-05-30 | 2015-12-03 | Incyte Corporation | Traitement de la leucémie neutrophile chronique (cnl) et de la leucémie myéloïde chronique atypique (acml) par des inhibiteurs de jak1 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| DK3746429T3 (da) | 2018-01-30 | 2022-05-02 | Incyte Corp | Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on) |
| BR122023022189A2 (pt) | 2018-02-16 | 2024-02-20 | Incyte Corporation | Usos de inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas |
| CN112423759A (zh) | 2018-03-30 | 2021-02-26 | 因赛特公司 | 使用jak抑制剂治疗化脓性汗腺炎 |
| MX2020010815A (es) | 2018-04-13 | 2020-12-11 | Incyte Corp | Biomarcadores para enfermedad de injerto contra hospedero. |
| EA202191170A1 (ru) | 2018-10-31 | 2021-07-27 | Инсайт Корпорейшн | Комбинированная терапия для лечения гематологических заболеваний |
| MX2021007260A (es) | 2018-12-19 | 2021-09-08 | Incyte Corp | Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales. |
-
2019
- 2019-03-29 EP EP19722968.5A patent/EP3775284A1/fr active Pending
- 2019-03-29 JP JP2020552754A patent/JP7565798B2/ja active Active
- 2019-03-29 WO PCT/US2019/024990 patent/WO2019191679A1/fr not_active Ceased
- 2019-03-29 US US16/369,724 patent/US11584961B2/en active Active
- 2019-03-29 MA MA052655A patent/MA52655A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021519772A (ja) | 2021-08-12 |
| JP7565798B2 (ja) | 2024-10-11 |
| US20200063188A1 (en) | 2020-02-27 |
| EP3775284A1 (fr) | 2021-02-17 |
| WO2019191679A1 (fr) | 2019-10-03 |
| US11584961B2 (en) | 2023-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52655A (fr) | Biomarqueurs pour maladie cutanée inflammatoire | |
| DK3806744T3 (da) | Øjeblikkelig undersøgelse | |
| IL277955A (en) | Biomarkers against host diseases in transplantation | |
| EP3465445A4 (fr) | Cohérence de cache pour traitement en mémoire | |
| DK3481964T3 (da) | Biomarkører for inflammatorisk tarmsygdom | |
| EP3818921C0 (fr) | Endoscope | |
| EP3824296A4 (fr) | Maladie du foie | |
| EP3701030A4 (fr) | Thérapies géniques pour maladie neurodégénérative | |
| IL277217A (en) | Use of anti-IL-36R antibodies to treat inflammatory bowel disease | |
| EP3633372A4 (fr) | Biomarqueur pour la maladie d'alzheimer | |
| EP3335041A4 (fr) | Biomarqueurs pour le traitement de la pelade | |
| EP3887396A4 (fr) | Thérapies géniques pour maladie neurodégénérative | |
| EP3803372C0 (fr) | Microscope à ultrasons | |
| EP3887514A4 (fr) | Édition de gène thérapeutique pour une maladie associée à elane | |
| EP3820487A4 (fr) | Édition de gènes pour troubles auto-immuns | |
| EP3817663C0 (fr) | Caméra compton adaptative pour imagerie médicale | |
| EP3730141A4 (fr) | Agent thérapeutique pour la pollakiurie nocturne | |
| IL280199A (en) | Receptor for vista | |
| EP4002602A4 (fr) | Connecteur | |
| EP3999703A4 (fr) | Articulation à charnière | |
| MA55882A (fr) | Spéculum vaginal | |
| EP3870699A4 (fr) | Traitements pour la maladie de charcot-marie-tooth | |
| EP3903725A4 (fr) | Structure de jonction pour traitement | |
| EP3635402A4 (fr) | Biomarqueur de maladie | |
| EP3745939A4 (fr) | Endoscope |